Survodutide Achieves 17% Weight Loss in Phase 3 Obesity Trial
Survodutide achieves 17% weight loss in Phase 3 obesity trial, with distinct body composition benefits compared to existing GLP-1...
FDA Oncology Panel Rejects AstraZeneca’s Novel Trial Design Framework, 6-3
FDA oncology panel votes 6-3 to reject AstraZeneca's novel trial design framework for breast cancer drug approval, signaling stricter...
FDA Places Clinical Hold on Newron’s Evenamide Schizophrenia Trial After Patient Death
FDA clinical hold placed on Newron's evenamide schizophrenia trial following a patient death during Phase 3 enrollment.
The Eight Hours Clinicians Ignored: How Albus Health Is Turning Sleep Into a Clinical Endpoint
Mikesh Udani CEO, Albus Health For decades, respiratory medicine has measured what patients do during the day—spirometry in clinic,...
The Disease-Modification Bet in Pulmonary Arterial Hypertension
Sten R. Sörensen CEO and Board Member, Cereno Scientific Pulmonary arterial hypertension kills most patients within seven years of...
NMN in ITP: A Phase 1/2 Signal That Should Rewrite How We Design Rare Disease Trials
A phase 1/2 NMN trial in immune thrombocytopenia just posted a clean safety signal and platelet response data that...
Pioneering BCI Lets Stroke Patient Control PC With His Mind
A fully implanted, wireless brain-computer interface enabled a post-stroke participant to control a computer, including a functional Pong task,...
First Patient Enrolled in AXPALXI™ Wet AMD Extension Trial
Ocular Therapeutix has enrolled the first participant in SOL-X, a 36‑month open-label extension study evaluating long-term safety and outcomes...
Rein Therapeutics Phase 2 Trial Update for LTI-03 in IPF
Eight patients have been enrolled to date in Rein Therapeutics’ randomized, placebo-controlled Phase 2 RENEW trial of LTI-03 for...
OPTIMAL-PSMA Trial: A Promising New Hope for Prostate Cancer
Initial dosimetry from the randomized Phase 2 OPTIMAL-PSMA study indicates TLX597-Tx delivers higher tumor uptake with low salivary gland...